THL Partners has agreed to acquire a majority stake in US-based clinical trial network Headlands Research from KKR in a transaction valued at around $600m, according to a report by Reuters citing sources familiar with the matter.
KKR founded Headlands in 2018 to consolidate a fragmented market of stand-alone trial sites and leverage technology to scale operations. Since its inception, Headlands has grown to more than 20 sites and completed over 5,000 trials across therapeutic areas such as CNS disorders, vaccines, and metabolic diseases.
Headlands’ growth reflects the expanding demand for clinical research services, fuelled by big pharma’s increased R&D spend, the emergence of new therapies, and AI-driven drug development. Private equity firms have been active in the space, with recent deals including BayPine’s $1.5bn acquisition of CenExel and Genstar Capital’s majority stake in Flourish Research.
For THL, the acquisition builds on two decades of investment in pharma services, with previous portfolio companies including Syneos Health, PCI Pharma Services, Adare Pharma Solutions, and Red Nucleus. The firm plans to accelerate Headlands’ expansion, enhance its technology infrastructure, and strengthen its ability to deliver diverse, high-quality trial data.
The transaction is said to have generated a strong return for KKR, which previously achieved a six-fold gain from its 2021 sale of PRA Health Sciences to Icon for $12bn.
